Wedbush Lifts Earnings Estimates for ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Wedbush lifted their Q1 2025 earnings estimates for ORIC Pharmaceuticals in a research note issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.50) per share for the quarter, up from their previous forecast of ($0.52). Wedbush has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.95) EPS, FY2026 earnings at ($1.81) EPS and FY2027 earnings at ($1.95) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.01.

Several other analysts have also weighed in on ORIC. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Friday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Wells Fargo & Company assumed coverage on ORIC Pharmaceuticals in a research report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 target price for the company. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $18.86.

ORIC Pharmaceuticals Stock Performance

Shares of ORIC stock opened at $7.84 on Friday. ORIC Pharmaceuticals has a fifty-two week low of $6.33 and a fifty-two week high of $16.65. The stock’s fifty day moving average price is $9.27 and its two-hundred day moving average price is $9.48. The company has a market cap of $556.85 million, a PE ratio of -4.31 and a beta of 1.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new stake in ORIC Pharmaceuticals during the fourth quarter worth approximately $50,000. BNP Paribas Financial Markets bought a new position in shares of ORIC Pharmaceuticals during the 4th quarter worth approximately $71,000. Creative Planning acquired a new stake in shares of ORIC Pharmaceuticals during the 3rd quarter worth approximately $116,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of ORIC Pharmaceuticals in the 3rd quarter valued at $132,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after acquiring an additional 2,520 shares during the period. 95.05% of the stock is owned by institutional investors.

Insider Activity at ORIC Pharmaceuticals

In related news, CEO Jacob Chacko sold 24,660 shares of ORIC Pharmaceuticals stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $204,184.80. Following the completion of the transaction, the chief executive officer now owns 778,648 shares of the company’s stock, valued at $6,447,205.44. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Dominic Piscitelli sold 8,851 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,286.28. Following the completion of the transaction, the chief financial officer now owns 106,764 shares in the company, valued at approximately $884,005.92. The trade was a 7.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,361 shares of company stock worth $350,749 over the last ninety days. Insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.